The Subject Expert Committee (SEC) of India’s Central Drugs Standard Control Organisation (CDSCO) has recommended emergency use of Bharat Biotech’s Covid-19 vaccine, Covaxin, for children and adolescents aged two to 18 years. Earlier this month, the company, which concluded the Phase II/III clinical trials of the shot in children, presented the results to CDSCO for verification and to obtain emergency use authorisation, PTI reported.

Russia has announced plans to study a nasal spray form of the Sputnik V Covid-19 vaccine developed by the Gamaleya Research Institute in adult subjects in the wake of a rising number of cases in the country. As per a document published on the state register of medicines, the nasal spray will be administered in two doses to subjects at a clinic in St Petersburg, Reuters reported. Further details of the tests were not divulged.

The Vietnam Ministry of Health has granted approval to Arcturus Therapeutics to commence the Phase IIIb segment of the Phase I/II/III clinical trial assessing Covid-19 vaccine candidate ARCT-154 against the SARS-CoV-2 Delta variant and other variants of concern. The Phase IIIb trial has started dosing subjects and plans to enrol nearly 20,000 people. These participants will be given either two doses of the vaccine administered at a gap of 28 days or a placebo.